Cas:58735-58-3 2-(Bromomethyl)-4-chloro-1-methoxybenzene manufacturer & supplier

Chemical Name:2-(Bromomethyl)-4-chloro-1-methoxybenzene

CAS.NO:58735-58-3

Synonyms:5-chloro-2-methoxybenzylbromide

Molecular Formula:C₈H₈BrClO

Molecular Weight:235.50600

HS Code:2909309090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:N/A

Density:N/A

Index of Refraction:

PSA:9.23000

Exact Mass:233.94500

LogP:3.24350

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 5-chloro-2-methoxybenzylbromide chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,5-chloro-2-methoxybenzylbromide physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,5-chloro-2-methoxybenzylbromide Use and application,5-chloro-2-methoxybenzylbromide technical grade,usp/ep/jp grade.

Related News: From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry. 2-(Bromomethyl)-4-chloro-1-methoxybenzene manufacturer Mankind Pharmaceuticals on Monday said it has inked a licensing pact with Glenmark Pharmaceuticals to co-market diabetes drug Remogliflozin Etabonate in the country. 2-(Bromomethyl)-4-chloro-1-methoxybenzene supplier Characteristic APIs represented by cardiovascular, antiviral, antitumor and other categories are targeted at generic APIs with patent expiring original research drugs, which have high scientific and technological content and rich profits. They have developed in China in the past decade. The more active API segment has contributed to the rise of Huahai Pharmaceutical, Chuangnuo Pharmaceutical, and Jiangbei Pharmaceutical. 2-(Bromomethyl)-4-chloro-1-methoxybenzene vendor One key question for the fixed-duration combo is whether it can sustain remission after treatment has stopped. In the preliminary analysis of the GLOW trial, at three months after treatment ended, 51.9% of the Imbruvica-Venclexta patients had undetectable measurable residual disease (uMRD)—a stringent marker reflecting no signs of cancer—in bone marrow, versus 17.1% for the control group. The rates for peripheral blood were 54.7% and 39% for the two groups, respectively. 2-(Bromomethyl)-4-chloro-1-methoxybenzene factory From basic chemical raw materials to chemical preparations, complex chemical and physical processes are required. The production of chemical raw materials and intermediates concentrates the main synthetic procedures and technical links, which is the prerequisite and important guarantee for the development of the chemical pharmaceutical industry.